“ Every transaction is unique, and my goal is always to help my clients achieve their business goals while protecting their legal interests.
Rufus has over 20 years of experience advising clients on a wide range of transactional matters involving technology and intellectual property.
Rufus advises companies in a broad range of industries, including:
Among other things, Rufus represents clients with respect to inbound and outbound license agreements, development and commercialization agreements, co-marketing and co-promotion arrangements, collaborative research, strategic sourcing, equipment, manufacturing, supply and distribution agreements and other transactions. Rufus has also advised clients extensively in connection with complex patent licensing transactions, including patent exhaustion issues, patent sales and acquisitions, patent strategy, FRAND licensing issues, as well as intellectual property aspects of domestic and cross-border M&A transactions.
Rufus is qualified to practice law in the United States and in Germany and has experience in international intellectual property matters and global cross-border transactions involving the United States, Europe, and Asia.
Among others, clients he has advised include:
Rufus holds advanced degrees in law in the United States and Germany. He is recognized by IAM 1000 as one of the World’s Leading Patent Professionals, by Legal 500 as a member of our Tier 1 Patent Licensing and Technology Transactions Practices, and by Managing IP as a Transactions Star.
Rufus has been a guest lecturer at Stanford Law School, teaching on international copyright licensing and an adjunct professor at USF School of Law for international intellectual property law.Show More
AccuWeather in licensing transactions and the formation of a joint venture with Huafeng Media Group, the commercial weather media company owned by the China Meteorological Administration, for the distribution of enhanced weather information in China.
Advanced Micro Fabrication Equipment, Inc. (AMEC) on IP issues in connection with the settlement of certain disputes with Applied Materials, Inc.
Astellas Pharmaceuticals, Inc. on a license agreement with Ironwood Pharmaceuticals regarding the exclusive development and commercialization by Astellas of Ironwood’s linaclotide compound in Asia.
Autodesk on intellectual property licensing issues and its future collaboration with FIT AG in the field of additive manufacturing in connection with Autodesk’s acquisition of netfabb GmbH, a German software developer, from FIT AG.
Astellas Pharma Inc. in the acquisition of its partner Mitobridge, Inc., a biotechnology company that focuses on mitochondrial therapeutics.
BlackBerry in a strategic alliance and licensing transaction with the largest media, content, and technology business in Indonesia, PT Elang Mahkota Teknologi Tbk. (Emtek), to accelerate and advance BBM cross-platform offerings.
EW Scripps and United Media on IP issues in connection with their sale of rights in Charles Schulz’s “Peanuts” comic strips and characters to Iconix Brand Group and Schulz’s heirs.
Freescale Semiconductor, Inc. on IP issues in connection with the sale of its Imaging Systems Group to Conexant Systems, Inc.
Freescale Semiconductor, Inc. on IP issues in connection with the sale of its Gallium Arsenide (GaAs) power amplifier business to Skyworks Solutions, Inc.
Fujitsu Limited on IP and commercial law issues in its collaboration with Sun Microsystems, Inc. (now Oracle) regarding the development and commercialization of server products.
Gree Inc. on IP issues in connection with its acquisition of mobile social games developer Funzio, Inc.
Gruppo Campari on IP issues in connection with its $575 million purchase of the Wild Turkey brand and related assets from Pernod Ricard.
Hortonworks in a transaction with IBM focused on extending data science and machine learning across the Apache Hadoop ecosystem by combining Hortonworks Data Platform (HDP®) with IBM Data Science Experience and IBM Big SQL into new integrated solutions.
Immune-Onc Therapeutics on an exclusive global license and collaboration agreement with the University of Texas Health Science Center at Houston and the University of Texas Southwestern Medical Center to develop and commercialize novel biotherapeutics with applications in cancer immunotherapy and other diseases.
Intel Corporation on IP issues in connection with its $650 million acquisition of LSI’s Axxia Networking Business from Avago Technologies Limited.
Intel Corporation in its strategic alliance with China-based Tsinghua Unigroup and Spreadtrum Communications for the design and marketing of Intel architecture-based mobile SoC platforms for smartphones.
Intel Corporation in its strategic alliance with China-based Rockchip for the design and marketing of Intel architecture-based mobile SoC platforms for tablets.
Intel Corporation on IP issues in connection with its acquisition of Intelligent Dialogue Systems, S.L. (Indisys), a Spanish company that provides businesses with natural language and dialogue management solutions.
Intel Corporation on IP issues in connection with its acquisition of Mashery.
Intel Corporation on its $375 million acquisition from InterDigital of roughly 1,700 patents and patent applications primarily related to wireless communication technologies.
Intel Corporation on IP issues in connection with its $1.4 billion purchase of Infineon Technologies AG’s Wireless Solutions business.
Intercell AG on marketing and distribution agreement with Novartis for Intercell’s Japanese Encephalitis vaccine in Europe, the United States, and certain other markets.
Intercell AG in its strategic alliance with Biological E Ltd. for the development, manufacture, and commercialization of Japanese Encephalitis vaccine in Asia.
Intercell AG on several agreements with Merck & Co., Inc. regarding the development and commercialization of a vaccine against Group A Streptococcus and Staphylococcus aureus infections.
A leading supplier of mobile handsets on license and collaboration agreements with major semiconductor companies regarding the design and supply of 3G chipsets.
A major consumer products company on copyright and other IP issues in connection with an online music talent competition.
NCR Corporation on IP issues in connection with its acquisition of Israel-based retail software and services company Retalix Ltd., a stock purchase transaction valued at approximately $650 million and the largest public acquisition of an Israeli company announced in 2012.
Netlist, Inc. in a joint development and license agreement with Samsung Electronics to develop NVDIMM-P (NV-P) memory solutions based on Samsung’s NAND Flash and DRAM and Netlist’s HyperVault technology.
Netlist, Inc. on a loan and patent monetization transaction with Fortress Investment Group LLC.
Nikon Metrology on settlement and commercial agreements with Hexagon Metrology related to coordinate measuring arms.
Nikon Corporation on a license agreement with KLA Tencor, Inc. related to overlay measuring equipment.
Nikon Corporation on complex settlement and cross-license agreements with ASML Holding N.V. and Carl Zeiss SMT AG related to lithography equipment.
ON Semiconductor Corporation on IP issues in connection with its $31 million acquisition of Cypress Semiconductor Corporation’s image sensor business unit.
Otto Group in its acquisition of the “Bombay” trademarks and related assets from Hilco Consumer Capital and Gordon Brothers Group.
Santen on intellectual property issues in its acquisition of InnFocus, a development-stage medical device company developing the MicroShunt, a biocompatible drainage device implanted in the eye to drain eye fluid and reduce intraocular pressure, as a glaucoma treatment.
Santen Pharmaceutical Co., Ltd. in a transaction with Bayer for the marketing and co-promotion of VEGF Trap-Eye (for treatment of age-related macular degeneration) in Japan.
An in-licensing agreement for the exclusive rights from AbClon, a Korean company, to develop and commercialize a novel antibody product for treating gastric and breast cancers in China.
Shanghai Henlius Biotech, Inc. (“Henlius”) in its license agreement with Accord Healthcare Ltd. (“Accord”) for HLX02 – a Recombinant Humanized Anti-HER2 Monoclonal Antibody for Injection developed by Henlius.
Obtaining exclusive rights from Koltan Pharmaceuticals to develop and commercialize a novel antibody product for treating gastric, lung, and liver cancers in Asia.
SoftBank Group Corp. and SoftBank Vision Fund in the $40 billion sale of UK-headquartered multinational semiconductor and software design company Arm Limited to U.S. chip company NVIDIA.
The Bill & Melinda Gates Foundation on various transactions to ensure global access to vaccines and improved diagnostic products to combat Covid-19, TB, Malaria and other infectious diseases in the developing world.
The Bill & Melinda Gates Foundation on deals with Abbott and SD Biosensor to make 120 million rapid diagnostic tests for the coronavirus available to low- and middle-income countries.
Threshold Pharmaceuticals in its agreement with Merck KGaA for the development and commercialization of Threshold’s cancer candidate, TH-302, with Threshold receiving up to $550 million in upfront fees and potential development and commercialization milestone payments as well as royalties.
Uphill on intellectual property issues in connection with its acquisition of Integrated Silicon Solution, Inc., a fabless semiconductor company that designs and markets high-performance integrated circuits.